Bangladesh Ziska Pharmaceuticals Lorlatinib/Lorlatinib What is the drug?

Lorlatinib/Lorlatinib is a multi-kinase inhibitor used to treat patients with ALK-positive or ROS-1-positive metastatic non-small cell lung cancer. Bangladesh Zisika Pharmaceuticals is a large pharmaceutical company in Bangladesh that has been in existence for 35 years. It has advanced drug quality control and production lines, and the quality of the drugs is guaranteed. This drug has been launched in Bangladesh and has government approval. The quality of the drugs and all aspects are guaranteed.

The most common (incidence ≥20%)adverse reactions and Grade 3-4 laboratory abnormalities with lorlatinib are edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough. Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, and FPS. Activities of span>TRKA, TRKB, TRKC, FAK, FAK2 and ACK. Lorlatinib has shown activity in vitro against multiple mutated forms of the ALK enzyme, including some mutations detected in tumors undergoing disease progression with crizotinib and other ALK inhibitors. In mice implanted subcutaneously with tumors containing EML4 fusions harboring ALKvariants 1 or ALKmutations, including theG1202R andI1171T mutations detected in tumors upon disease progression on ALK inhibitor treatment, resulted in antitumor activity with lorlatinib. The current retail price of generic drugs in pharmaceutical factories100mg30 tablets3 is around one thousand, If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.